| Q38491230 | 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia |
| Q101118296 | SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation |
| Q73652047 | A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype |
| Q53719961 | A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0). |
| Q59211799 | A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia |
| Q43440810 | A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. |
| Q60358240 | ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles ofTP53disrupted chronic lymphocytic leukaemia cells |
| Q46851031 | Activation-induced cytidine deaminase and CD38 expression in B-cell chronic lymphocytic leukemia. |
| Q70597333 | All-trans retinoic acid plus low doses of cytarabine for the treatment of "poor-risk" acute myeloid leukemias |
| Q53950965 | Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). |
| Q47339225 | Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery |
| Q53330290 | Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. |
| Q36194530 | Apoptosis and immaturity in acute myeloid leukemia |
| Q55044243 | Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. |
| Q51025698 | Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. |
| Q74837523 | Automated haematology analysers in acute and chronic leukaemias |
| Q37837955 | B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage |
| Q40607052 | Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments |
| Q64124611 | Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease |
| Q80137020 | Bone marrow necrosis as a terminal complication of a very long-lasting polycythemia vera |
| Q44276636 | CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival |
| Q46467811 | CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells. |
| Q40085251 | CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target |
| Q53465248 | CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. |
| Q60358511 | CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance |
| Q58319764 | CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism |
| Q42770092 | CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia |
| Q35717883 | CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. |
| Q47836845 | CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias |
| Q38269513 | Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. |
| Q52646820 | Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. |
| Q59314784 | Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of MLL Gene Translocation Results in 378 Adult Patients |
| Q80477837 | Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients |
| Q33391903 | Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients |
| Q45988365 | Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. |
| Q78025533 | Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia |
| Q60358526 | Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia |
| Q36420752 | Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia |
| Q43558209 | Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia |
| Q33711084 | Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia. |
| Q79867238 | Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators |
| Q37064709 | Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients |
| Q73692109 | Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients |
| Q50477567 | Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. |
| Q58449091 | Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825 |
| Q58001030 | Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study |
| Q46902467 | Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. |
| Q40458874 | Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia |
| Q58370816 | Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia |
| Q37160624 | Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. |
| Q34461989 | Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. |
| Q87622131 | Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting |
| Q28539394 | Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor |
| Q79920761 | Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes |
| Q45762178 | Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. |
| Q58000969 | Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features |
| Q59314779 | Extensive toxic epidermal necrolysis following brentuximab vedotin administration |
| Q71614353 | FISH analysis for CML monitoring? |
| Q73480515 | Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+/MLL+ translocation in leukaemia |
| Q81045178 | Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy |
| Q38925105 | Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia |
| Q48307279 | Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia |
| Q81342804 | Gelatinous degeneration of the bone marrow: two case reports showing different hematological features and clinical outcomes |
| Q33371454 | Graft failure due to hemolytic uremic syndrome recurrence. |
| Q68222234 | High interleukin-6 plasma levels in acute promyelocytic leukemia |
| Q87724723 | High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma |
| Q41104416 | High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. |
| Q80193717 | Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient |
| Q58000974 | IGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia |
| Q35814897 | IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia |
| Q44558291 | Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter. |
| Q53640307 | Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). |
| Q51052377 | Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. |
| Q72395400 | Increased levels of circulating interleukin-6 in patients with newly diagnosed non-Hodgkin's lymphomas |
| Q33410699 | Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia |
| Q28394721 | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia |
| Q71102200 | Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors |
| Q37588785 | Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance |
| Q92372468 | KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival |
| Q71720000 | Leukocyte alkaline phosphatase score in plasma cell dyscrasias: correlation with disease severity and circulating levels of granulocyte-colony stimulating factor |
| Q83189246 | Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab |
| Q43052729 | MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. |
| Q38010501 | Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy |
| Q38232480 | Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. |
| Q87106192 | Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients |
| Q40983463 | Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosis. |
| Q58001001 | Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study |
| Q54387895 | Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. |
| Q69566429 | Molecular characterization of Ph' + hybrid acute leukemia |
| Q80292588 | Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow |
| Q60358355 | Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38+CD49d+chronic lymphocytic leukaemia cells |
| Q44078664 | Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia |
| Q35104356 | Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia. |
| Q42120007 | Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. |
| Q44752987 | Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. |
| Q43518448 | Mutational status of IgV(H) genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection? |
| Q60358020 | Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia |
| Q48140340 | NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. |
| Q52931736 | NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. |
| Q54345184 | NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. |
| Q58449125 | New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia |
| Q52935951 | Normal lymphocytes from leukemic samples as an internal quality control for fluorescence intensity in immunophenotyping of acute leukemias. |
| Q67561971 | O6-alkylguanine-DNA alkyltransferase activity in blasts obtained from patients with myelogenous or lymphocytic leukemia |
| Q45148064 | One year of clinical experience in postdilution hemofiltration with online reinfusion of regenerated ultrafiltrate. |
| Q52930409 | Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? |
| Q74469972 | Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors |
| Q38945688 | Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia |
| Q33758834 | Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells |
| Q38608451 | Pure erythroid leukemia in advanced breast cancer. |
| Q33489476 | Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study. |
| Q60358460 | Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia |
| Q33375482 | Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura |
| Q44409582 | Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia. |
| Q74428914 | Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera |
| Q36689156 | Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia |
| Q45191343 | Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling |
| Q54704847 | Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. |
| Q40366836 | Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance |
| Q42702972 | Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance |
| Q39404177 | The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. |
| Q36326340 | The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. |
| Q58000962 | The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience |
| Q51518841 | The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. |
| Q54693168 | The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. |
| Q79894989 | The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia |
| Q54323506 | The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. |
| Q46497211 | Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. |
| Q72112536 | Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (M0) |
| Q34453174 | Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia |
| Q43437611 | Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab. |
| Q60358588 | ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations |